News >

Expert Discusses Guidelines, Next Steps With MPNs

Chelsea LoCascio
Published: Monday, Dec 04, 2017

Brady L. Stein, MD

Brady L. Stein, MD
Updates to the NCCN guidelines on myeloproliferative neoplasms (MPNs) will drastically change how these diseases are managed, according to Brady L. Stein, MD.

on Hematologic Malignancies, Stein, an associate professor of medicine at Feinberg School of Medicine at Northwestern University, discussed the differences between the types of MPNs, the NCCN guideline changes, and the important role of JAK inhibitors.

OncLive: Can you share insight on the updates to the NCCN guidelines that include MPNs?

Stein: What is most important is that these somewhat rare entities finally have guidelines. They finally have some guidance for decision making in the setting of a relatively rare illness that had been previously unrepresented. I focused on the 3 classical MPNs: essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication